Excel Industries Ltd
Excel Industries Q3 FY26: Revenue ₹233.5 Cr, PAT ₹8.4 Cr
Q3 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Excel Industries Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q3 FY26 revenue: ₹233.5 Cr (Standalone and Consolidated), up 18.9-19% YoY from ₹196.4 Cr in Q3 FY25 (Pages 6, 8, 9) - Volume growth in performance solutions driven by capacity expansion in biocides (Page 15) - Export revenue share: 27.0% of total revenue in Q3 FY26 (Page 5) - No explicit overall revenue or volume outlook provided for future quarters or fiscal years in the presentation (through Page 37) - Company plans Capex of Rs. Q3 FY26 EBITDA (Adjusted): ₹16.9 Cr (Standalone ₹17.1 Cr), +29-30% YoY - Q3 FY26 EBITDA Margin (Adjusted): 7.2% (Standalone 7.3%), up ~100 bps YoY - Q3 FY26 EBIT: ₹11.7 Cr (Standalone ₹11.7 Cr), +31-34% YoY - Q3 FY26 EBIT Margin: 5.0% (Standalone 5.0%) - Q3 FY26 Profit After Tax (PAT): ₹8.4 Cr (Standalone ₹8.4 Cr), +31-36% YoY - Q3 FY26 PAT Margin: 3.6% (Standalone 3.6%) - Revenue: ₹233.5 Cr, +19% YoY - Margin Outlook: No explicit future margin guidance or outlook stated in the presentation.
From Excel Industries Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 FY26 revenue: ₹233.5 Cr (Standalone and Consolidated), up 18.9-19% YoY from ₹196.4 Cr in Q3 FY25 (Pages 6, 8, 9)
- Volume growth in performance solutions driven by capacity expansion in biocides (Page 15)
- Export revenue share: 27.0% of total revenue in Q3 FY26 (Page 5)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Excel Industries Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Received Environmental Clearance (EC) for capacity increase and new product offerings including Phosphorus Pentasulphide, Diethyldithiophosphoryl Chloride, Diazotization Chemistry platform, Phosphonates, and Pharma capacities.
- Upgraded waste-water treatment capabilities to handle expanded volumes.
- Added volume capabilities for existing and new products at Vizag facility.
- Plan to invest Rs. 200–300 Crores over next three years in plant upgrades, product innovation, capacity expansion, technology.
- Rs. 40-50 Crores per year reserved for ongoing maintenance and improvements.
- Introduced capacities for new products like Sodium Trichloro Pyridinol (NaTCP), polymer additive, and HEDP 4Na.
- Technological advancements and asset maintenance ongoing at Lote and Roha sites.
- PCL3 new plant set up at Lote in 2023.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Excel Industries Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Excel Industries Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹281 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Excel Industries Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Balaji Amines Ltd (Q3 FY26)
Revenue from Operations for Q3FY26: ₹331.30 crore, compared to ₹320.59 crore in Q3FY25 (consolidated) and ₹304.68 crore in Q3FY25 (standalone). Key concall…
- Vidhi Specialty Food Ingredients Ltd (Q3 FY26)
94.5 Cr, down 4.1% YoY from Rs. Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Bodal Chemicals Ltd (Q3 FY26)
5,046.6 Mn, up 13.3% YoY (Q3 FY25: Rs. Key concall takeaways from Bodal Chemicals Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Chemcon Speciality Chemicals Ltd (Q3 FY26)
Q3 FY26 Revenue from Operations:** ₹57.3 Cr (vs ₹54.4 Cr in Q3 FY25) — approx. Key concall takeaways from Chemcon Speciality Chemicals Ltd's Q3 FY26 earnings…
Frequently Asked Questions
What were Excel Industries Ltd Q3 FY26 results?
Q3 FY26 revenue: ₹233.5 Cr (Standalone and Consolidated), up 18.9-19% YoY from ₹196.4 Cr in Q3 FY25 (Pages 6, 8, 9) - Volume growth in performance solutions driven by capacity expansion in biocides (Page 15) - Export revenue share: 27.0% of total revenue in Q3 FY26 (Page 5) - No explicit overall revenue or volume outlook provided for future quarters or fiscal years in the presentation (through Page 37) - Company plans Capex of Rs. Q3 FY26 EBITDA (Adjusted): ₹16.9 Cr (Standalone ₹17.1 Cr), +29-30% YoY - Q3 FY26 EBITDA Margin (Adjusted): 7.2% (Standalone 7.3%), up ~100 bps YoY - Q3 FY26 EBIT: ₹11.7 Cr (Standalone ₹11.7 Cr), +31-34% YoY - Q3 FY26 EBIT Margin: 5.0% (Standalone 5.0%) - Q3 FY26 Profit After Tax (PAT): ₹8.4 Cr (Standalone ₹8.4 Cr), +31-36% YoY - Q3 FY26 PAT Margin: 3.6% (Standalone 3.6%) - Revenue: ₹233.5 Cr, +19% YoY - Margin Outlook: No explicit future margin guidance or outlook stated in the presentation.
What is Excel Industries Ltd share price analysis?
Excel Industries Ltd currently shows a neutral. The stock trades at a P/E of 16.9 with a market cap of ₹1,205 Cr. Investors should review the full earnings analysis for detailed insights.
Is Excel Industries Ltd planning capital expenditure?
Received Environmental Clearance (EC) for capacity increase and new product offerings including Phosphorus Pentasulphide, Diethyldithiophosphoryl Chloride, Diazotization Chemistry platform, Phosphonates, and Pharma capacities.
Keep Excel Industries Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.